Recce Pharmaceuticals Adds Biotech Veteran Alan W. Dunton M.D. to its Board of Directors
On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors, stated Dr. John Prendergast, Recce Pharmaceuticals Non-Executive Chairman.
- On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors, stated Dr. John Prendergast, Recce Pharmaceuticals Non-Executive Chairman.
- Alan joins us at a critical time as we move into the second half of 2020, where we anticipate a number of human clinical trials evaluating our broad-spectrum novel antibiotic, RECCE 327.
- In addition, we will continue to investigate the efficacy of our synthetic compounds against SARS-CoV-2 among other key clinical development milestones.
- Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.